These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32891071)

  • 1. Non-alcoholic fatty liver disease (NAFLD) in Asia-More efforts are needed.
    Li J; Nguyen MH
    Liver Int; 2020 Dec; 40(12):3144. PubMed ID: 32891071
    [No Abstract]   [Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease in Asia: emerging perspectives.
    Seto WK; Yuen MF
    J Gastroenterol; 2017 Feb; 52(2):164-174. PubMed ID: 27637587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia.
    Hsu CS; Kao JH
    Expert Rev Gastroenterol Hepatol; 2017 Aug; 11(8):759-772. PubMed ID: 28613087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non alcoholic fatty liver: epidemiology and natural history.
    Masarone M; Federico A; Abenavoli L; Loguercio C; Persico M
    Rev Recent Clin Trials; 2014; 9(3):126-33. PubMed ID: 25514916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letter: substantial under-diagnosis of NAFLD - more efforts are needed globally.
    Emhmed Ali S; Nguyen MH
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1624. PubMed ID: 33085985
    [No Abstract]   [Full Text] [Related]  

  • 6. Alcoholic liver disease presents at advanced stage and progresses faster compared to non-alcoholic fatty liver diseas.
    Shoreibah M; Raff E; Bloomer J; Kakati D; Rasheed K; Kuo YF; Singal AK
    Ann Hepatol; 2016; 15(2):183-9. PubMed ID: 26845595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease.
    Tovoli F; Ferri S; Piscaglia F
    Curr Pharm Des; 2020; 26(32):3909-3914. PubMed ID: 32348210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
    Patel PJ; Banh X; Horsfall LU; Hayward KL; Hossain F; Johnson T; Stuart KA; Brown NN; Saad N; Clouston A; Irvine KM; Russell AW; Valery PC; Williams S; Powell EE
    Intern Med J; 2018 Feb; 48(2):144-151. PubMed ID: 29083080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment.
    Wong VW; Chan WK; Chitturi S; Chawla Y; Dan YY; Duseja A; Fan J; Goh KL; Hamaguchi M; Hashimoto E; Kim SU; Lesmana LA; Lin YC; Liu CJ; Ni YH; Sollano J; Wong SK; Wong GL; Chan HL; Farrell G
    J Gastroenterol Hepatol; 2018 Jan; 33(1):70-85. PubMed ID: 28670712
    [No Abstract]   [Full Text] [Related]  

  • 10. Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals.
    Della Pepa G; Vetrani C; Lombardi G; Bozzetto L; Annuzzi G; Rivellese AA
    Nutrients; 2017 Sep; 9(10):. PubMed ID: 28954437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV.
    Verna EC
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):211-223. PubMed ID: 28404136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.
    Li J; Zou B; Yeo YH; Feng Y; Xie X; Lee DH; Fujii H; Wu Y; Kam LY; Ji F; Li X; Chien N; Wei M; Ogawa E; Zhao C; Wu X; Stave CD; Henry L; Barnett S; Takahashi H; Furusyo N; Eguchi Y; Hsu YC; Lee TY; Ren W; Qin C; Jun DW; Toyoda H; Wong VW; Cheung R; Zhu Q; Nguyen MH
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):389-398. PubMed ID: 30902670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New trends on obesity and NAFLD in Asia.
    Fan JG; Kim SU; Wong VW
    J Hepatol; 2017 Oct; 67(4):862-873. PubMed ID: 28642059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
    Bertot LC; Adams LA
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial: screening for NAFLD - a promising strategy to mitigate future burden of liver disease.
    Sinha R; Lockman KA
    Aliment Pharmacol Ther; 2016 Jan; 43(1):163. PubMed ID: 26638929
    [No Abstract]   [Full Text] [Related]  

  • 19. The epidemiology of non-alcoholic fatty liver disease.
    Bellentani S
    Liver Int; 2017 Jan; 37 Suppl 1():81-84. PubMed ID: 28052624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty liver disease: diagnosis and investigation.
    Nascimbeni F; Loria P; Ratziu V
    Dig Dis; 2014; 32(5):586-96. PubMed ID: 25034292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.